Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Resch, B; Liziczai, K; Reiterer, F; Freidl, T; Haim, M; Urlesberger, B.
Respiratory syncytial virus associated hospitalizations in children with congenital diaphragmatic hernia.
Pediatr Neonatol. 2018; 59(2):184-188
Doi: 10.1016/j.pedneo.2017.08.005
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Resch Bernhard
- Co-Autor*innen der Med Uni Graz
- Freidl Thomas
- Haim Michaela
- Reiterer Friedrich
- Urlesberger Berndt
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- To evaluate the risk of RSV infection in infants and children with congenital diaphragmatic hernia (CDH) over two consecutive RSV seasons. Retrospective, single-center cohort study from southern Austria including infants with CDH born between 1993 and 2012. Infants were retrieved by searching via ICD-10 codes Q79.0 and Q79.1 and by using a local electronic database. Children were followed over 2 years of life including at least two consecutive RSV seasons (November to April). We also defined a group of hypothetical RSV infections with the following criteria: 70% of the admissions due to a respiratory infection (diagnosis of bronchiolitis and/or LRI score ≥3) during the RSV seasons over the first 2 years of life, when no test for RSV was performed. Twenty-nine of 45 infants with CDH comprised the study population (6 were lost to follow-up and 10 died) of whom 9 (31%) exhibited 17 hospitalizations due to respiratory illness. Two hospitalized infants (6.9% of the study population) tested RSV positive, one during the first and the other during the second RSV season. Nine of 29 infants (31%) had documentation of palivizumab prophylaxis, none (0%) had proven RSV hospitalization compared to 1 of 20 (5%) without prophylaxis during the first RSV season (p = 0.256). Including the hypothetical cases, we calculated 0 of 9 (0%) in the palivizumab group and 4 of 20 (20%) in the group without prophylaxis (p = 0.079). We found a moderate rate of proven RSV hospitalizations in infants with CDH, and palivizumab prophylaxis led to a non-significant reduction of proven and hypothesized RSV hospitalizations. Copyright © 2017. Published by Elsevier B.V.
- Find related publications in this database (using NLM MeSH Indexing)
- Antiviral Agents - therapeutic use
- Child -
- Female -
- Hernias, Diaphragmatic, Congenital - complications
- Hospitalization -
- Humans -
- Infant -
- Infant, Newborn -
- Male -
- Palivizumab - therapeutic use
- Respiratory Syncytial Virus Infections - etiology
- Retrospective Studies -
- Find related publications in this database (Keywords)
- respiratory syncytial virus
- congenital diaphragmatic hernia
- respiratory tract infection
- hospitalization